Therapeutic Use of Creatine in Brain or Heart Ischemia: Available Data and Future Perspectives

Medicinal Research Reviews

Volumn 33, Issue 2, 2013, Pages 336-363

  Perasso, Luisa ^a   Spallarossa, Paolo ^a   Gandolfo, Carlo ^a   Ruggeri, Piero ^a   Balestrino, Maurizio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Creatine; Ischemia; Myocardial infarction; Phosphocreatine; Stroke; Therapy

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE; CREATINE PHOSPHATE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE;

ANOXIA; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG SAFETY; ELECTRIC ACTIVITY; EXCITOTOXICITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; NEUROPROTECTION; NONHUMAN;

BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; CARDIOTONIC AGENTS; CREATINE; FEMALE; FORECASTING; HUMANS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; NEUROPROTECTIVE AGENTS; PHOSPHOCREATINE; STROKE; TREATMENT OUTCOME;

EID: 84873987487     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20255     Document Type: Article

References (202)

1. Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia-The ischemic penumbra. Stroke 1981;12:723-725.
2. Balestrino M. Pathophysiology of anoxic depolarization: New findings and a working hypothesis. J Neurosci Methods 1995;59:99-103.
3. Arsava EM, Gurer G, Gursoy-Ozdemir Y, Karatas H, Dalkara T. A new model of transient focal cerebral ischemia for inducing selective neuronal necrosis. Brain Res Bull 2009;78:226-231.
4. DeGirolami U, Crowell RM, Marcoux FW. Selective necrosis and total necrosis in focal cerebral ischemia. Neuropathologic observations on experimental middle cerebral artery occlusion in the macaque monkey. J Neuropathol Exp Neurol 1984;43:57-71.
5. Richard MJP, Saleh TM, El Bahh B, Zidichouski JA. A novel method for inducing focal ischemia in vitro. J Neurosci Methods 2010;190:20-27.
6. Broughton BRS, Reutens DC, Sobey CG. Apoptotic mechanisms after cerebral ischemia. Stroke 2009;40:e331-e339.
7. Moro MA, Almeida A, Bolanos JP, Lizasoain I. Mitochondrial respiratory chain and free radical generation in stroke. Free Radic Biol Med 2005;39:1291-1304.
8. Strong AJ, Anderson PJ, Watts HR, Virley DJ, Lloyd A, Irving EA, Nagafuji T, Ninomiya M, Nakamura H, Dunn AK, Graf R. Peri-infarct depolarizations lead to loss of perfusion in ischaemic gyrencephalic cerebral cortex. Brain 2007;130:995-1008.
9. Arundine M, Tymianski M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci 2004;61:657-668.
10. Hertz L. Bioenergetics of cerebral ischemia: A cellular perspective. Neuropharmacology 2008;55:289-309.
11. Tatsumi T, Shiraishi J, Keira N, Akashi K, Mano A, Yamanaka S, Matoba S, Fushiki S, Fliss H, Nakagawa M. Intacellular ATP is required for mitochondrial apoptotic pathways in isolated hypoxic rat cardiac myocytes. Cardiovasc Res 2003;59:428-440.
12. Clarke DD, Sokoloff L. Circulation and energy metabolism of the brain. In: Siegel GJ, Agranoff BW, Wayne Albers R, Fisher SK, Uhler MD, editors. Basic neurochemistry. Philadelphia, PA: Lippincott Wiliams & Wilkins; 1999. pp 638-669.
13. Sokoloff L. Relation between physiological function and energy metabolism in the central nervous system. J Neurochem 1977;29:13-26.
14. Erecinska M, Silver IA. ATP and brain function. J Cereb Blood Flow Metab 1989;9:2-19.
15. Andres RH, Ducray AD, Schlattner U, Wallimann T, Widmer HR. Functions and effects of creatine in the central nervous system. Brain Res Bull 2008;76:329-343.
16. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev 2000;80:1107-1213.
17. Brewer GJ, Wallimann TW. Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons. J Neurochem 2000;74:1968-1978.
18. Balestrino M, Lensman M, Parodi M, Perasso L, Rebaudo R, Melani R, Polenov S, Cupello A. Role of creatine and phosphocreatine in neuronal protection from anoxic and ischemic damage. Amino Acids 2002;23:221-229.
19. Whittingham TS, Lipton P. Cerebral synaptic transmission during anoxia is protected by creatine. J Neurochem 1981;37:1618-1621.
20. Sestili P, Martinelli C, Colombo E, Barbieri E, Potenza L, Sartini S, Fimognari C. Creatine as an antioxidant. Amino Acids 2011:1-12.
21. Sestili P, Martinelli C, Bravi G, Piccoli G, Curci R, Battistelli M, Falcieri E, Agostini D, Gioacchini AM, Stocchi V. Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. Free Radic Biol Med 2006;40:837-849.
22. Perasso L, Cupello A, Lunardi GL, Principato C, Gandolfo C, Balestrino M. Kinetics of creatine in blood and brain after intraperitoneal injection in the rat. Brain Res 2003;974:37-42.
23. Dechent P, Pouwels PJ, Wilken B, Hanefeld F, Frahm J. Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. Am J Physiol 1999;277:R698-R704.
24. Ipsiroglu OS, Stromberger C, Ilas J, Hoger H, Muhl A, Stockler-Ipsiroglu S. Changes of tissue creatine concentrations upon oral supplementation of creatine-monohydrate in various animal species. Life Sci 2001;69:1805-1815.
25. Tachikawa M, Hosoya K, Ohtsuki S, Terasaki T. A novel relationship between creatine transport at the blood-brain and blood-retinal barriers, creatine biosynthesis, and its use for brain and retinal energy homeostasis. Subcell Biochem 2007;46:83-98.
26. Braissant O, Beard E, Torrent C, Henry H. Dissociation of AGAT, GAMT and SLC6A8 in CNS: Relevance to creatine deficiency syndromes. Neurobiol Dis 2010;37:423-433.
27. Béard E, Braissant O. Synthesis and transport of creatine in the CNS: Importance for cerebral functions. J Neurochem 2010;115:297-313.
28. Snow RJ, Murphy RM. Creatine and the creatine transporter: A review. Mol Cell Biochem 2001;224:169-181.
29. Lipton P, Whittingham TS. Reduced ATP concentrations as a basis for synaptic transmission failure during hypoxia in the in vitro guinea-pig hippocampus. J Physiol 1982;325:51-65.
30. Yoneda K, Arakawa T, Asaoka Y, Fukuoka Y, Kinugasa K, Takimoto K, Okada Y. Effects of accumulation of phosphocreatine on utilization and restoration of high-energy phosphates during anoxia and recovery in thin hippocampal slices from the guinea pig. Exp Neurol 1983;82:215-222.
31. Balestrino M, Rebaudo R, Lunardi G. Exogenous creatine delays anoxic depolarization and protects from hypoxic damage: Dose-effect relationship. Brain Res 1999;816:124-130.
32. Bures J, Buresova O, Krivanek J. The mechanisms and applications of Leao's spreading depression of electroencephalographic activity. Academia (Publishing House of the Czechoslovak Academy of Sciences) and Academic Press, Prague and New York, 1974.
33. Leao AAP. Spreading depression of activity in the cerebral cortex. J Neurophys 1947;7:359-390.
34. Hansen AJ. Effect of anoxia on ion distribution in the brain. Physiol Rev 1985;65:101-148.
35. +)ATPase with ouabain induces spreading depression-like depolarization in hippocampal slices. Brain Res 1999;838:37-44.
36. Hansen AJ, Zeuthen T. Extracellular ion concentrations during spreading depression and ischemia in the rat brain cortex. Acta Physiol Scand 1981;113:437-445.
37. Cox JA, Lysko PG, Henneberry RC. Excitatory amino acid neurotoxicity at the N-methyl-D-aspartate receptor in cultured neurons: Role of the voltage-dependent magnesium block. Brain Res 1989;499:267-272.
38. Lysko PG, Cox JA, Vigano MA, Henneberry RC. Excitatory amino acid neurotoxicity at the N-methyl-D-aspartate receptor in cultured neurons: Pharmacological characterization. Brain Res 1989;499:258-266.
39. Rami A, Krieglstein J. Neuronal protective effects of calcium antagonists in cerebral ischemia. Life Sci 1994;55:2105-2113.
40. Horn J, Limburg M. Calcium antagonists for ischemic stroke. Stroke 2001;32:570-576.
41. Kemp JA, McKernan RM. NMDA receptor pathways as drug targets. Nat Neurosci Suppl 2002;5:1039-1042.
42. Carafoli E. The ambivalent nature of the calcium signal. J Endocrinol Invest 2004;27:134-136.
43. Balestrino M, Somjen GG. Chlorpromazine protects brain tissue in hypoxia by delaying spreading depression-mediated calcium influx. Brain Res 1986;385:219-226.
44. Perez-Pinzon MA, Mumford PL, Sick TJ. Prolonged anoxic depolarization exacerbates NADH hyperoxidation and promotes poor electrical recovery after anoxia in hippocampal slices. Brain Res 1998;786:165-170.
45. Balestrino M. Pathophysiology of anoxic depolarization: New findings and a working hypothesis. J Neurosci Methods 1995;59:99-103.
46. Jarvis CR, Anderson TR, Andrew RD. Anoxic depolarization mediates acute damage independent of glutamate in neocortical brain slices. Cereb Cortex 2001;11:249-259.
47. Kaminogo M, Suyama K, Ichikura A, Onizuka M, Shibata S. Anoxic depolarization determines ischemic brain injury. Neurol Res 1998;20:343-348.
48. Zapara TA, Simonova OG, Zharkikh AA, Balestrino M, Ratushniak AS. Seasonal differences and protection by creatine or arginine pretreatment in ischemia of mammalian and molluscan neurons in vitro. Brain Res 2004;1015:41-49.
49. Roberts PJ, Davies SW. Excitatory receptors and their role in excitotoxicity. Biochem Soc Trans 1987;15:218-219.
50. Novelli A, Reilly JA, Lysko PG, Henneberry RC. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 1988;451:205-212.
51. Tsuji K, Nakamura Y, Ogata T, Shibata T, Kataoka K. Rapid decrease in ATP content without recovery phase durino glutamate-induced cell death in cultured spinal neurons. Brain Res 1994;662:289-292.
52. 2+ and energy levels durino in vitro ischemia in the gerbil hippocampal slice. J Neurochem 1994;62:626-634.
53. Amara SG, Pacholczyk T. Sodium-dependent neurotransmitter reuptake systems. Curr Opin Neurobiol 1991;1:84-90.
54. Monyer H, Giffard RG, Hartley DM, Dugan LL, Goldberg MP, Choi DW. Oxygen or glucose deprivation-induced neuronal injury in cortical cell cultures is reduced by tetanus toxin. Neuron 1992;8:967-973.
55. Koch HP, Chamberlein AR, Bridges RJ. Nontransportable inhibitors attenuate reversal of glutamate uptake in synaptosomes following a metabolic insult. Mol Pharmacol 1999;55:1044-1048.
56. Carter AJ, Muller RE, Pschorn U, Stransky W. Preincubation with creatine enhances levels of creatine phosphate and prevents anoxic damage in rat hippocampal slices. J Neurochem 1995;64:2691-2699.
57. Brustovetsky N, Brustovetsky T, Dubinsky JM. On the mechanisms of neuroprotection by creatine and phosphocreatine. J Neurochem 2001;76:425-434.
58. Bu G, Maksymovitch EA, Nerbonne JM, Schwartz AL. Expression and function of the low density lipoprotein receptor-related protein (LRP) in mammalian central neurons. J Biol Chem 1994;269:18521-18528.
59. Bernardi P, Basso E, Colonna R, Costantini P, Di Lisa F, Eriksson O, Fontane E, Forte M, Ichas F, Massari S, Nicolli A, Petronilli V, Scorrano L. Perspectives of the mitochondrial permeability transition pore. Biochim Biophys Acta 1998;1365:200-206.
60. Halestrap AP. A pore way to die: The role of mitochondria in reperfusion injury and cardioprotection. Biochem Soc Trans 2010;38:841-860.
61. Brdiczka D, Beutner G, Ruck A, Dolder M, Wallimann T. The molecular structure of mitochondrial contact sites. Their role in regulation of energy metabolism and permeability transition. Biofactors 1998;8:235-242.
62. Dolder M, Walzel B, Speer O, Schlattner U, Wallimann T. Inhibition of the mitochondrial permeability transition by creatine kinase substrates. J Biol Chem 2003;278:17760-17766.
63. O'Gorman E, Beutner G, Dolder M, Koretsky AP, Brdiczka D, Wallimann T. The role of creatine kinase inhibition of mitochondrial permeability transition. FEBS Lett 1997;414:253-257.
64. Sullivan PG, Geiger JD, Mattson MP, Scheff SW. Dietary supplement creatine protects against traumatic brain injury. Ann Neurol 2000;48:723-729.
65. Klivenyi P, Calingasan NY, Starkov A, Stavrovskaya IG, Kristal BS, Yang L, Wieringa B, Beal MF. Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiol Dis 2004;15:610-617.
66. Persky AM, Brazeau GA. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev 2001;53:161-176.
67. Lawler JM, Barnes WS, Wu GY, Song W, Demaree S. Direct antioxidant properties of creatine. BBRC 2002;290:47-52.
68. Sestili P, Diamantini G, Bedini A, Cerioni L, Tommasini I, Tarzia G, Cantoni O. Plant-derived phenolic compounds prevent the DNA single-strand breakage and cytotoxicity induced by tert-butylhydroperoxide via an iron-chelating mechanism. Biochem J 2002;364:121-128.
69. Azzi A, Davies KJ, Kelly F. Free radical biology-terminology and critical thinking. FEBS Lett 2004;558:3-6.
70. Wyss M, Schulze A. Health implications of creatine: Can oral creatine supplementation protect against neurological and atherosclerotic disease? Neuroscience 2002;112:243-260.
71. White BC, Grossman LI, O'Neil BJ, DeGracia DJ, Neumar RW, Rafols JA, Krause GS. Global brain ischemia and reperfusion. Ann Emerg Med 1996;27:588-594.
72. Harukuni I, Bhardwaj A. Mechanisms of brain injury after global cerebral ischemia. Neurol Clin 2006;24:1-21.
73. Michaelis T, Wick M, Fujimori H, Matsumura A, Frahm J. Proton MRS of oral creatine supplementation in rats. Cerebral metabolite concentrations and ischemic challenge. NMR Biomed 1999;12:309-314.
74. Wick M, Fujimori H, Michaelis T, Frahm J. Brain water diffusion in normal and creatine-supplemented rats during transient global ischemia. Magn Reson Med 1999;42:798-802.
75. Adcock KH, Nedelcu J, Loenneker T, Martin E, Wallimann T, Wagner BP. Neuroprotection of creatine supplementation in neonatal rats with transient cerebral hypoxia-ischemia. Dev Neurosci 2002;24:382-388.
76. Berger R, Middelanis J, Vaihinger HM, Mies G, Wilken B, Jensen A. Creatine protects the immature brain from hypoxic-ischemic injury. J Soc Gynecol Investig 2004;11:9-15.
77. Ireland Z, Dickinson H, Snow R, Walker DW. Maternal creatine: Does it reach the fetus and improve survival after an acute hypoxic episode in the spiny mouse (Acomys cahirinus)? Am J Obstet Gynecol 2008;198:431.e1-431.e6.
78. Braissant O, Henry H, Loup M, Eilers B, Bachmann C. Endogenous synthesis and transport of creatine in the rat brain: An in situ hybridization study. Mol Brain Res 2001;86:193-201.
79. Ohtsuki S, Tachikawa M, Takanaga T, Shimizu H, Watanabe TM, Hosoya K, Terasaki T. The blood-brain barrier creatine transporter is a major pathway for supplying creatine to the brain. J Cereb Blood Flow Metab 2002;22:1327-1335.
80. Otellin VA, Korzhevskii DE, Kostkin VB, Balestrino M, Lensman MV, Polenov SA. The neuroprotective effect of creatine in rats with cerebral ischemia. Dokl Biol Sci 2003;390:197-199.
81. Durukan A, Tatlisumak T. Ischemic stroke in mice and rats. Methods Mol Biol 2009;573:95-114.
82. Zhu S, Li M, Figueroa BE, Liu A, Stavrovskaya IG, Pasinelli P, Beal MF, BrownJr RH, Kristal BS, Ferrante RJ, Friedlander RM. Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. J Neurosci 2004;24:5909-5912.
83. Prass K, Royl G, Lindauer U, Freyer D, Megow D, Dirnagl U, Stockler-Ipsiroglu G, Wallimann T, Priller J. Improved reperfusion and neuroprotection by creatine in a mouse model of stroke. J Cereb Blood Flow Metab 2007;27:452-459.
84. Christie DL. Functional insights into the creatine transporter. In: Salomons G, Wyss M, editors. Creatine and creatine kinase in health and disease. Dordrecht, The Netherlands: Springer; 2007. pp 99-118.
85. Roberts JJ, Walker JB. Synthesis and accumulation of an extremely stable high-energy phosphate compound by muscle, heart, and brain of animals fed the creatine analog, 1-carboxyethyl-2-iminoimidazolidine (homocyclocreatine). Arch Biochem Biophys 1983;220:563-571.
86. Woznicki DT, Walker JB. Utilization of cyclocreatine phosphate, an analogue of creatine phosphate, by mouse brain during ischemia and its sparing action on brain energy reserves. J Neurochem 1980;34:1247-1253.
87. Artru AA, Michenfelder JD. Cyclocreatine phosphate, an analogue of creatine phosphate, does not improve hypoxic tolerance in mice. J Neurochem 1982;39:1198-1200.
88. Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah DR, Beal MF. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 1999;157:142-149.
89. Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah DR, Beal MF. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci 1998;18:156-163.
90. Martin KJ, Chen SF, Clark GM, Degen D, Wajima M, Von Hoff DD, Kaddurah-Daouk R. Evaluation of creatine analogues as a new class of anticancer agents using freshly explanted human tumor cells. J Natl Cancer Inst 1994;86:608-613.
91. Teicher BA, Menon K, Northey D, Liu J, Kufe DW, Kaddurah-Daouk R. Cyclocreatine in cancer chemotherapy. Cancer Chemother Pharmacol 1995;35:411-416.
92. Lunardi G, Parodi A, Perasso L, Pohvozcheva AV, Scarrone S, Adriano E, Florio T, Gandolfo C, Cupello A, Burov SV, Balestrino M. The creatine transporter mediates the uptake of creatine by brain tissue, but not the uptake of two creatine-derived compounds. Neuroscience 2006;142:991-997.
93. Perasso L, Lunardi G, Risso F, Pohvozcheva A, Leko M, Gandolfo C, Florio T, Cupello A, Burov S, Balestrino M. Protective effects of some creatine derivatives in brain tissue anoxia. Neurochem Res 2008;33:765-775.
94. Perasso L, Adriano E, Ruggeri P, Burov SV, Gandolfo C, Balestrino M. In vivo neuroprotection by a creatine-derived compound: Phosphocreatine-Mg-complex acetate. Brain Res 2009;1285:158-163.
95. Kubler W, Katz AM. Mechanism of early "pump" failure of the ischemic heart: Possible role of adenosinetriphosphate depletion and inorganic phosphate accumulation. Am J Cardiol 1977;40:467-471.
96. Hearse DJ. Oxygen deprivation and early myocardial contractile failure: A reassessment of the possible role of adenosinetriphosphate. Am J Cardiol 1979;44:1115-1121.
97. Hearse DJ, Garlick PM, Humphrey SM. Ischemic contracture of the myocardium: Mechanisms and prevention. Am J Cardiol 1977;39:986-993.
98. Jennings RB, Reimer KA. Lethal myocardial ischemic injury. Am J Pathol 1981;102:241-255.
99. Reibel DK, Rovetto MJ. Myocardial ATP synthesis and mechanical function following oxygen deficiency. Am J Physiol 1978;234:H620-H624.
100. Reimer KA, Hill ML, Jennings RB. Prolonged depletion of ATP because of delayed repletion of the adenine nucleotide pool following reversible myocardial ischemic injury in dogs. Adv Myocardiol 1983;4:395-407.
101. Reimer KA, Jennings RB, Hill ML. Total ischemia in dog hearts in vitro. 2. High energy phosphate depletion and associated defects in energy metabolism, cell volume regulation and sarcolemmal integrity. Circ Res 1981;49:901-911.
102. Parratt JR, Marshall RJ. The response of isolated cardiac muscle to acute anoxia: Protective effect of adenosine triphosphate and creatine phosphate. J Pharm Pharmacol 1974;26:427-433.
103. Seraydarian MW, Artaza L, Abbott BC. Creatine and the control of energy metabolism in cardiac and skeletal muscle cells in culture. J Molec Cell Cardiol 1974;6:405-413.
104. Van Brussel E, Yang JJ, Seraydarian MW. Isozymes of creatine kinase in mammalian cell cultures. J Cell Physiol 1983;116:221-226.
105. Fagbemi O, Kane KA, Parratt JR. Creatine phosphate suppresses ventricular arrhythmias resulting from coronary artery ligation. J Cardiovasc Pharmacol 1982;4:53-58.
106. Zucchi R, Poddighe R, Limbruno U, Mariani M, Ronca-Testoni S, Ronca G. Protection of isolated rat heart from oxidative stress by exogenous creatine phosphate. J Mol Cell Cardiol 1989;21:67-73.
107. Millaoye-Van Brussel E, Freyss-Beguin M, Griffaton G, Lechat P. Energy metabolism of cardiac cell cultures during oxygen deprivation: Effects of creatine and arachidonic acid. Biochem Pharmacol 1985;34:145-147.
108. Mastroroberto P, Chello M, Di Tommaso L, Marchese AR. The effects of creatine phosphate in experimental myocardial infarction. Curr Ther Res Clin Exp 1996;57:552-558.
109. Woo YJ, Grand TJ, Zentko S, Cohen JE, Hsu V, Atluri P, Berry MF, Taylor MD, Moise MA, Fisher O, Kolakowski S. Creatine phosphate administration preserves myocardial function in a model of off-pump coronary revascularization. J Cardiovasc Surg (Torino) 2005;46:297-305.
110. Hearse DJ, Brainbridge MV, Jynge P. Ischemia and reperfusion: The progression and prevention of tissue injury. In: Hearse DJ, Braimbridge MV, Jynge P, editors. Protection of the ischemic myocardium: Cardioplegia; New York: Raven Press, 1981. p 21-49.
111. Hearse DJ, Brainbridge MV, Jynge P. Methods of assessment and results of cardiac surgery using cardioplegia. In: Hearse DJ, Brainbridge MV, Jynge P, editors. Protection of the ischemic myocardium: Cardioplegia; New York: Raven Press; 1981. p 375-410.
112. Engleman RM, Rousou JH, Longo F. The time course of myocardial high-energy phosphate degradation during potassium cardioplegic arrest. Surgery 1979;86:138-147.
113. Balderman SC, Binette JP, Chan AWK. The optimal temperature for preservation of the myocardium during global ischemia. Ann Thorac Surg 1983;35:605-614.
114. Lange R, Ingwall J, Hale SL. Preservation of high energy phosphates by verapamil in reperfused myocardium. Circulation 1984;70:734-741.
115. Kissin I, Cavender JB. Effect of propranolol on energy demand-supply balance in myocardial ischemia. J Cardiovasc Pharmacol 1981;3:992-1001.
116. Robinson LA, Braimbridge MV, Hearse DJ. Enhanced myocardial protection with high-energy phosphates in St. Thomas' Hospital cardioplegic solution. Synergism of adenosine triphosphate and creatine phosphate. J Thorac Cardiovasc Surg 1987;93:415-427.
117. Thelin S, Hultman J, Ronquist G, Juhlin C, Hansson HE. Metabolic and functional effects of creatine phosphate in cardioplegic solution. J Thorac Cardiovasc Surg 1987;21:39-45.
118. Thelin S, Hultman J, Ronquist G. Improved myocardial protection by creatine phosphate in cardioplegic solution. An in vivo study in the pig during normothermic ischemia. J Thorac Cardiovasc Surg 1987;35:137-142.
119. Pastoris O, Dossena M, Vercesi L, Bruseghini M, Pagnin A, Ceriana P. Biochemical changes induced in the myocardial cell during cardioplegic arrest supplemented with creatine phosphate. J Cardiothorac Vasc Anesth 1991;5:475-480.
120. Chambers DJ, Haire K, Morley N, Fairbanks L, Strumia E, Young CP, Venn GE. St. Thomas' hospital cardioplegia: Enhanced protection with exogenous creatine phosphate. Ann Thorac Surg 1996;61:67-75.
121. Roberts JJ, Walker JB. Feeding a creatine analogue delays ATP depletion and onset of rigor in ischemic heart. Am J Physiol Heart C Physiol 1982;12:H911-H916.
122. Jacobstein MD, Gerken TA, Bhat AM, Carlier PG. Myocardial protection during ischemia by prior feeding with the creatine analog: Cyclocreatine. J Am Coll Cardiol 1989;14:246-251.
123. Osbakken M, Ito K, Zhang D, Ponomarenko I, Ivanics T, Jahngen EG, Cohn M. Creatine and cyclocreatine effects on ischemic myocardium: 31P nuclear magnetic resonance evaluation of intact heart. Cardiology 1992;80:184-195.
124. Volek JS, Rawson ES. Scientific basis and practical aspects of creatine supplementation for athletes. Nutrition 2004;20:609-614.
125. Clark JF. Creatine: A review of its nutritional applications in sport. Nutrition 1998;14:322-324.
126. Mercimek-Mahmutoglu S, Stoeckler-Ipsiroglu S, Adami A, Appleton R, Araujo HC, Duran M, Ensenauer R, Fernandez-Alvarez E, Garcia P, Grolik C, Item CB, Leuzzi V, Marquardt I, Muhl A, Saelke-Kellermann RA, Salomons GS, Schulze A, Surtees R, van der Knaap MS, Vasconcelos R, Verhoeven NM, Vilarinho L, Wilichowski E, Jakobs C. GAMT deficiency: Features, treatment, and outcome in an inborn error of creatine synthesis. Neurology 2006;67:480-484.
127. Battini R, Alessandri MG, Leuzzi V, Moro F, Tosetti M, Bianchi MC, Cioni G. Arginine: Glycine amidinotransferase (AGAT) deficiency in a newborn: Early treatment can prevent phenotypic expression of the disease. J Pediatr 2006;148:828-830.
128. Tarnopolsky MA, Mahoney DJ, Vajsar J, Rodriguez C, Doherty TJ, Roy BD, Biggar D. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 2004;62:1771-1777.
129. Felber S, Skladal D, Wyss M, Kremser C, Koller A, Sperl W. Oral creatine supplementation in Duchenne muscular dystrophy: A clinical and 31P magnetic resonance spectroscopy study. Neurol Res 2000;22:145-150.
130. Komura K, Hobbiebrunken E, Wilichowski EK, Hanefeld FA. Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. Pediatr Neurol 2003;28:53-58.
131. Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky MA. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007;35:235-242.
132. O'Reilly DS, Carter R, Bell E, Hinnie J, Galloway PJ. Exercise to exhaustion in the second-wind phase of exercise in a case of McArdle's disease with and without creatine supplementation. Scott Med J 2003;48:46-48.
133. Vorgerd M, Zange J, Kley R, Grehl T, Husing A, Jager M, Muller K, Schroder R, Mortier W, Fabian K, Malin JP, Luttmann A. Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease-Double-blind, placebo-controlled crossover study. Arch Neurol 2002;59:97-101.
134. Vorgerd M, Grehl T, Jager M, Muller K, Freitag G, Patzold T, Bruns N, Fabian K, Tegenthoff M, Mortier W, Luttmann A, Zange J, Malin J-P. Creatine therapy in myophosphorylase deficiency (McArdle disease). A placebo-controlled crossover trial. Arch Neurol 2000;57:956-963.
135. Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, Urbinelli L, Qureshi M, Zhang H, Pestronk A, Caress J, Donofrio P, Sorenson E, Bradley W, Lomen-Hoerth C, Pioro E, Rezania K, Ross M, Pascuzzi R, Heiman-Patterson T, Tandan R, Mitsumoto H, Rothstein J, Smith-Palmer T, MacDonald D, Burke D. A clinical trial of creatine in ALS. Neurology 2004;63:1656-1661.
136. Vielhaber S, Kaufmann J, Kunz WS. Creatine effects in ALS Motor cortices revealed by in vivo localized proton magnetic resonance spectroscopy. Journal of the Neurological Sciences 2002;199:S6-S8.
137. Vielhaber S, Kaufmann J, Kanowski M, Sailer M, Feistner H, Tempelmann C, Elger CE, Heinze HJ, Kunz WS. Effect of creatine supplementation on metabolite levels in ALS motor cortices. Exp Neurol 2001;172:377-382.
138. Atassi N, Ratai EM, Greenblatt D, Cudkowicz M, DiBernardo A. A phase I, dosage-escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. Neurotherapeutics 2010;7:329.
139. Mazzini L, Balzarini C, Colombo R, Mora G, Pastore I, De Ambrogio R, Caligari M. Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: Preliminary results. J Neurol Sci 2001;191:139-144.
140. Smith CA, Chetlin RD, Gutmann L, Yeater RA, Alway SE. Effects of exercise and creatine on myosin heavy chain isoform composition in patients with Charcot-Marie tooth disease. Muscle Nerve 2006;34:586-594.
141. Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, Como P, Zimmerman C, Lin M, Zhang L, Ulug AM, Beal MF, Matson W, Bogdanov M, Ebbel E, Zaleta A, Kaneko Y, Jenkins B, Hevelone N, Zhang H, Yu H, Schoenfeld D, Ferrante R, Rosas HD. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006;66:250-252.
142. Bender A, Auer DP, Merl T, Reilmann R, Saemann P, Yassouridis A, Bender J, Weindl A, Dose M, Gasser T, Klopstock T. Creatine supplementation lowers brain glutamate levels in Huntington's disease. J Neurol 2005;252:36-41.
143. Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AH, Warner TT. High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study. Neurology 2005;64:1655-1656.
144. Verbessem P, Lemiere J, Eijnde BO, Swinnen S, Vanhees L, Van Leemputte M, Hespel P, Dom R. Creatine supplementation in Huntington's disease: A placebo-controlled pilot trial. Neurology 2003;61:925-930.
145. Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AHV, Warner TT. Creatine therapy for Huntington's disease: Clinical and MRS findings in a 1-year pilot study. Neurology 2003;61:141-142.
146. Roitman S, Green T, Osher Y, Karni N, Levine J. Creatine monohydrate in resistant depression: A preliminary study. Bipolar Disord 2007;9:754-758.
147. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol 2008;31:141-150.
148. Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschl M, Gekeler F, Muller-Myhsok B, Gasser T, Tatsch K, Klopstock T. Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial. Neurology 2006;67:1262-1264.
149. The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66:664-671.
150. Vahedi K, Domigo V, Amarenco P, Bousser MG. Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building. J Neurol Neurosurg Psychiatry 2000;68:112-113.
151. Kammer RT. Lone atrial fibrillation associated with creatine monohydrate supplementation. Pharmacotherapy 2005;25:762-764.
152. Thorsteinsdottir B, Grande JP, Garovic VD. Acute renal failure in a young weight lifter taking multiple food supplements, including creatine monohydrate. J Ren Nutr 2006;16:341-345.
153. Whitt KN, Ward SC, Deniz K, Liu L, Odin JA, Qin L. Cholestatic liver injury associated with whey protein and creatine supplements. Semin Liver Dis 2008;28:226-231.
154. Do KD, Bellabarba C, Bhananker SM. Exertional rhabdomyolysis in a bodybuilder following overexertion: A possible link to creatine overconsumption. Clin J Sport Med 2007;17: 78-79.
155. Robinson SJ. Acute quadriceps compartment syndrome and rhabdomyolysis in a weight lifter using high-dose creatine supplementation. J Am Board Fam Pract 2000;13:134-137.
156. Chorny JA, Cohen J. Pigmented purpuric dermatosis associated with creatine supplementation. Arch Dermatol 2006;142:1662-1663.
157. Greenhaff P. Renal dysfunction accompanying oral creatine supplements. Lancet 1998;352:233.
158. Poortmans JR, Francaux M. Adverse effects of creatine supplementation: Fact or fiction? Sports Med 2000;30:155-170.
159. Rooney K, Bryson J, Phuyal J, Denyer G, Caterson I, Thompson C. Creatine supplementation alters insulin secretion and glucose homeostasis in vivo. Metabolism 2002;51:518-522.
160. Rooney KB, Bryson JM, Digney AL, Rae CD, Thompson CH. Creatine supplementation affects glucose homeostasis but not insulin secretion in humans. Ann Nutr Metab 2003;47:11-15.
161. Gualano B, Novaes RB, Artioli GG, Freire TO, Coelho DF, Scagliusi FB, Rogeri PS, Roschel H, Ugrinowitsch C, Lancha AH. Effects of creatine supplementation on glucose tolerance and insulin sensitivity in sedentary healthy males undergoing aerobic training. Amino Acids 2008.
162. Gualano B, de SP, V, Roschel H, Artioli GG, Junior MN, Lucia de Sa PA, Rossi da Silva ME, Cunha MR, Otaduy MC, da Costa LC, Ferreira JC, Pereira RM, Brum PC, Bonfa E, Lancha AJ. Creatine in type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Med Sci Sports Exerc 2010.
163. Juhn MS, Tarnopolsky M. Potential side effects of oral creatine supplementation: A critical review. Clin J Sport Med 1998;8:298-304.
164. Schilling BK, Stone MH, Utter A, Kearney JT, Johnson M, Coglianese R, Smith L, O'Bryant HS, Fry AC, Starks M, Keith R, Stone ME. Creatine supplementation and health variables: A retrospective study. Med Sci Sports Exerc 2001;33:183-188.
165. Shao A, Hathcock JN. Risk assessment for creatine monohydrate. Regul Toxicol Pharmacol 2006;3:242-251.
166. Groeneveld GJ, Beijer C, Veldink JH, Kalmijn S, Wokke JH, van den Berg LH. Few adverse effects of long-term creatine supplementation in a placebo-controlled trial. Int J Sports Med 2005;26:307-313.
167. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999;79:1431-1568.
168. Kass IR, Lipton P. Mechanisms involved in irreversible anoxic damage to the in vitro rat hippocampal slice. J Physiol (London) 1982;332:459-472.
169. Yoneda K, Okada Y. Effects of anoxia and recovery on the neurotransmission and level of high-energy phosphates in thin hippocampal slices from the guinea-pig. Neuroscience 1989;28:401-407.
170. Lensman M, Korzhevskii DE, Mourovets VO, Kostkin VB, Izvarina N, Perasso L, Gandolfo C, Otellin VA, Polenov SA, Balestrino M. Intracerebroventricular administration of creatine protects against damage by global cerebral ischemia in rat. Brain Res 2006;1114:187-194.
171. Otellin VA, Korzhevskii DE, Kostkin VB, Balestrino M, Lensman M, Polenov S. Neuroprotective effect of creatine in cerebral ischemia. Doklady Akademyy Nauk 2003;390:406-408.
172. Prass K, Royl G, Lindauer U, Freyer D, Megow D, Dirnagl U, Stockler-Ipsiroglu G, Wallimann T, Priller J. Improved reperfusion and neuroprotection by creatine in a mouse model of stroke. J Cereb Blood Flow Metab 2007;27:452-459.
173. Di Loreto S, Balestrino M. Development of vulnerability to hypoxic damage in in vitro hippocampal neurons. Int J Dev Neurosci 1997;15:225-230.
174. Savitz SI, Fisher M. Prophylactic neuroprotection. Curr Drug Targets 2007;8:846-849.
175. McKhann GM, Grega MA, Borowicz LMJ, Bechamps M, Selnes OA, Baumgartner WA, Royall RM. Encephalopathy and stroke after coronary artery bypass grafting. Arch Neurol 2002;59:1422-1428.
176. Rees K, Beranek-Stanley M, Burke M, Ebrahim S. Hypothermia to reduce neurological damage following coronary artery bypass surgery. Cochrane Database Syst Rev 2001;1:CD002138.
177. Wilken B, Ramirez JM, Probst I, Richter DW, Hanefeld F. Anoxic ATP depletion in neonatal mice brainstem is prevented by creatine supplementation. Arch Dis Child Fetal Neonatal Ed 2000;82:F224-F227.
178. Lisabeth LD, Ireland JK, Risser JMH, Brown DL, Smith MA, Garcia NM, Morgenstern LB. Stroke risk after transient ischemic attack in a population-based setting. Stroke 2004;35:1842-1846.
179. Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS, Bernstein AL, Sidney S. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 2007;369:283-292.
180. Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: A systematic review and meta-analysis. Lancet Neurol 2007;6:1063-1072.
181. de Lau LM, den Hertog HM, van den Herik EG, Koudstaal PJ. Predicting and preventing stroke after transient ischemic attack. Expert Rev Neurother 2009;9:1159-1170.
182. Balestrino M, Gandolfo C, Perasso L. Controlling the flow of energy: Inhibition and stimulation of the creatine transporter. Curr Enzyme Inhib 2009;5:223-233.
183. Hill MD. Stroke: The dashed hopes of neuroprotection. Lancet Neurol 2007;6:2-3.
184. Young AR, Ali C, Duretete A, Vivien D. Neuroprotection and stroke: Time for a compromise. J Neurochem 2007;103:1302-1309.
185. Rebaudo R, Melani R, Carita F, Rosi L, Picchio V, Ruggeri P, Izvarina N, Balestrino M. Increase of cerebral phosphocreatine in normal rats after intracerebroventricular administration of creatine. Neurochem Res 2000;25:1493-1495.
186. Kreuter J. Application of nanoparticles for the delivery of drugs to the brain. Int Congr Series 2005;1277:85-94.
187. Schroder U, Sabel BA. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res 1996;710:121-124.
188. López-Viota Julián, Mandal S, Delgado AV, Toca-Herrera JL, Möller Marco, Zanuttin F, Balestrino M, Krol S. Electrophoretic characterization of gold nanoparticles functionalized with human serum albumin (HSA) and creatine. J Colloid Interface Sci 2009;332:215-223.
189. Rauchova H, Koudelova J, Drahota Z, Mourek J. Hypoxia-induced lipid peroxidation in rat brain and protective effect of carnitine and phosphocreatine. Neurochem Res 2002;27: 899-904.
190. Weinbergova O, Zeman K, Komarek J, Kolbel F, Metelka R, Ostransky J. Dynamics of some biochemical indices in myocardial infarction treated with thrombolysis and creatine phosphate. Acta Univ Palacki Olomuc Fac Med 1996;140:94.
191. Reimers B, Maddalena F, Cacciavillani L, Resta M, Marzari A, la Volta S. Phosphocreatine in acute myocardial infarction: A multicentric randomized study. Cuore 1994;11:345-354.
192. Lee TH, Poole WK, Gustafson N, Stone PH, Jaffe AS, Muller JE, Sobel BE, Roberts R, Braunwald E. Rate of disappearance of creatine kinase-MB after acute myocardial infarction: Clinical determinants of variability. Am Heart J 1988;116:1493-1499.
193. Lavin F, Kane M, Forde A, Gannon F, Daly K. Comparison of five cardiac markers in the detection of reperfusion after thrombolysis in acute myocardial infarction. Br Heart J 1995;73:422-427.
194. Soslau G, McKenzie RJ, Brodsky I, Devlin TM. Extracellular ATP inhibits agonist-induced mobilization of internal calcium in human platelets. Biochim Biophys Acta 1995;1268:73-80.
195. 0-[beta-thio]diphosphate occur by distinct mechanisms. Biochem J 1991;276:621-630.
196. Panchenko EP, Shalaev SV, Giorgadze ML. Phosphocreatine: Thrombocyte aggregation in patients with stenocardia. Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR 1987;10:39-41.
197. Panchenko E, Dobrovolsky A, Rogoza A, Sorokin E, Ageeva N, Markova L, Titaeva E, Anuchin V, Karpov Y, Saks V. The effect of exogenous phosphocreatine on maximal walking distance, blood rheology, platelet aggregation, and fibrinolysis in patients with intermittent claudication. Int Angiol 1994;13:59-64.
198. Camilova UK, Katsenovich RA, Kostco SZ. Combined use of phosphocreatine and nifedipine for treatment of patients with acute myocardial infarction. Curr Ther Res Clin Exp 1991;50:591-598.
199. Ruda MY, Samarenko MB, Afonskaya NI, Saks VA. Reduction of ventricular arrhythmias by phosphocreatine (Neoton) in patients with acute myocardial infarction. Am Heart J 1988;116:393-397.
200. Behar S, Kishon Y, Reicher-Reiss H, Zion M, Kaplinsky E, Abinader E, Agmon J, Friedman Y, Barzilai J, Kauli N. Prognosis of early versus late ventricular fibrillation complicating acute myocardial infarction. Int J Cardiol 1994;45:191-198.
201. Rosenshtraukh LV, Saks VA, Yuriavichus IA, Nesterenko VV, Undrovinas AI, Smirnov VN, Chazov EI. Effect of creatine phosphate on the slow inward calcium current, action potential, and contractile force of frog atrium and ventricle. Biochem Med 1979;21:1-15.
202. Salomons G, Van Dooren S, Verhoeven N, Marsden D, Schwartz C, Cecil K, DeGrauw T, Jakobs C. X-linked creatine transporter defect: An overview. J Inherit Metab Dis 2003;26:309-318.